Form 4: Tyra Biosciences CEO Todd Harris Sells Shares Under 10b5-1 Trading Plan

Sentiment:

SEC Form 4 Filing


Tyra Biosciences' CEO, Todd Harris, executed multiple sales of common stock between September 23rd and September 25th, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

  • Todd Harris, the President and CEO of Tyra Biosciences, sold shares of common stock over three days.
  • On September 23, 2024, he sold 10,092 shares at a weighted average price of $24.1257.
  • On September 24, 2024, he sold 1,055 shares at a weighted average price of $24.0196.
  • On September 25, 2024, he sold 600 shares at a weighted average price of $24.01.
  • These sales were executed under a Rule 10b5-1 trading plan adopted in December 2022.
  • Following these transactions, Harris directly owns 1,477,873 shares of Tyra Biosciences common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock sales by an executive. It's neutral in tone and doesn't inherently indicate positive or negative sentiment.

Risks

  • Executive stock sales can sometimes be perceived negatively by investors, potentially impacting the stock price.

Industry Context

Insider trading activity is common and closely monitored in the biotech industry. Rule 10b5-1 plans are frequently used to allow insiders to sell shares without being accused of trading on non-public information.

Stakeholder Impact

  • Shareholders may react to the news of the CEO selling shares, although the existence of a 10b5-1 plan mitigates potential concerns.

Key Dates

DateDescription
December 2022Date of adoption of the Rule 10b5-1 trading plan
09/23/2024First transaction date: Sale of 10,092 shares
09/24/2024Second transaction date: Sale of 1,055 shares
09/25/2024Third transaction date: Sale of 600 shares

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.